Literature DB >> 3444795

The pathogenesis and treatment of Graves' ophthalmopathy.

I R Jones1.   

Abstract

Entities:  

Mesh:

Year:  1987        PMID: 3444795      PMCID: PMC2428550          DOI: 10.1136/pgmj.63.743.731

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


× No keyword cloud information.
  23 in total

Review 1.  Studies on the pathogenesis of Graves' ophthalmopathy (with some related observations regarding therapy).

Authors:  J P Kriss; J Konishi; M Herman
Journal:  Recent Prog Horm Res       Date:  1975

2.  Treatment of thyrotoxicosis with 131 I; a review of 500 cases.

Authors:  G W BLOMFIELD; H ECKERT; M FISHER; H MILLER; D S MUNRO; G M WILSON
Journal:  Br Med J       Date:  1959-01-10

3.  Binding of thyroglobulin and thyroglobulin-antithyroglobulin immune complex to extraocular muscle membrane.

Authors:  J Konishi; M M Herman; J P Kriss
Journal:  Endocrinology       Date:  1974-08       Impact factor: 4.736

4.  Failure of retro-orbital tissue to neutralize the biological activity of the long-acting thyroid stimulator.

Authors:  J Shillinglaw; R D Utiger
Journal:  J Clin Endocrinol Metab       Date:  1968-07       Impact factor: 5.958

5.  Serum thyroglobulin, its autoantibody and thyroid stimulating antibodies in the endocrine exophthalmos.

Authors:  U Feldt-Rasmussen; A Kemp; K Bech; S N Madsen; J Date
Journal:  Acta Endocrinol (Copenh)       Date:  1981-02

6.  Delayed hypersensitivity in Graves' disease and exophthalmos: identification of thyroglobulin in normal human orbital muscle.

Authors:  B R Mullin; R E Levinson; A Friedman; D E Henson; R J Winand; L D Kohn
Journal:  Endocrinology       Date:  1977-02       Impact factor: 4.736

7.  A study of human leukocyte D locus related antigens in Graves' disease.

Authors:  N R Farid; L Sampson; E P Noel; J M Barnard; R Mandeville; B Larsen; W H Marshall; N D Carter
Journal:  J Clin Invest       Date:  1979-01       Impact factor: 14.808

8.  Cell-mediated immunity in the exophthalmos of Graves' disease as demonstrated by the migration inhibition factor (MIF) test.

Authors:  R E Munro; L Lamki; V V Row; R Volpé
Journal:  J Clin Endocrinol Metab       Date:  1973-08       Impact factor: 5.958

9.  An evaluation of plasma exchange for Graves' ophthalmopathy.

Authors:  W Kelly; D Longson; D Smithard; R Fawcitt; R Wensley; J Noble; J Keeley
Journal:  Clin Endocrinol (Oxf)       Date:  1983-05       Impact factor: 3.478

10.  Effect on exophthalmos of various methods of treatment of Graves' disease.

Authors:  G Gwinup; A N Elias; M S Ascher
Journal:  JAMA       Date:  1982-04-16       Impact factor: 56.272

View more
  1 in total

1.  Soluble IL-2 receptor levels in patients with Graves' ophthalmopathy.

Authors:  M F Prummel; W M Wiersinga; R Van der Gaag; M P Mourits; L Koornneef
Journal:  Clin Exp Immunol       Date:  1992-06       Impact factor: 4.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.